Why "Metabolic" Should Come First in Cardiovascular-Kidney Disease Naming
The proposed Met-CVRD nomenclature places metabolic dysfunction as the primary driver of the cardiovascular-renal disease syndrome, not just a comorbidity.
Quick Facts
What This Study Found
Metabolic dysfunction drives cardiovascular-renal disease and deserves primary positioning in the syndrome nomenclature as Met-CVRD.
Key Numbers
No specific trial data; conceptual paper with terminology proposal.
How They Did This
Expert commentary/nomenclature proposal with pathophysiological rationale.
Why This Research Matters
Naming matters — putting "metabolic" first prioritizes upstream treatment of the root cause rather than downstream management of heart and kidney symptoms.
The Bigger Picture
This nomenclature shift could influence clinical guidelines, research priorities, and drug development toward metabolic-first treatment strategies.
What This Study Doesn't Tell Us
Expert opinion/nomenclature proposal — no new clinical data. Name adoption requires consensus across multiple specialties.
Questions This Raises
- ?Will the Met-CVRD terminology be adopted by major guideline committees?
- ?Does metabolic-first treatment actually improve long-term outcomes more than organ-specific approaches?
Trust & Context
- Key Stat:
- Met-CVRD Proposed nomenclature placing metabolic dysfunction as the primary driver of cardiovascular-renal disease
- Evidence Grade:
- Expert commentary — provides conceptual framework supported by existing evidence but no new data.
- Study Age:
- Published in 2025, reflecting the evolving understanding of metabolic disease as a systemic driver.
- Original Title:
- Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.
- Published In:
- Diabetes/metabolism research and reviews, 41(6), e70083 (2025)
- Authors:
- Pozzilli, Paolo(2), Messina, Maria Vittoria, Roden, Michael(2)
- Database ID:
- RPEP-13099
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
What is Met-CVRD?
A proposed name for the syndrome where metabolic dysfunction (insulin resistance, inflammation, ectopic fat) drives both cardiovascular and kidney disease.
Why does the name of a disease matter?
Putting "metabolic" first emphasizes treating the root cause — metabolic dysfunction — rather than just managing heart and kidney symptoms individually.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13099APA
Pozzilli, Paolo; Messina, Maria Vittoria; Roden, Michael. (2025). Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.. Diabetes/metabolism research and reviews, 41(6), e70083. https://doi.org/10.1002/dmrr.70083
MLA
Pozzilli, Paolo, et al. "Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nomenclature.." Diabetes/metabolism research and reviews, 2025. https://doi.org/10.1002/dmrr.70083
RethinkPeptides
RethinkPeptides Research Database. "Metabolic Cardiovascular Renal Disease (Met-CVRD): A New Nom..." RPEP-13099. Retrieved from https://rethinkpeptides.com/research/pozzilli-2025-metabolic-cardiovascular-renal-disease
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.